.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Mallinckrodt
Citi
Argus Health
McKinsey
McKesson
Johnson and Johnson
Chinese Patent Office
Queensland Health

Generated: November 21, 2017

DrugPatentWatch Database Preview

FERRIPROX Drug Profile

« Back to Dashboard

Which patents cover Ferriprox, and what generic Ferriprox alternatives are available?

Ferriprox is a drug marketed by Apopharma Inc and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-two patent family members in twenty-four countries.

The generic ingredient in FERRIPROX is deferiprone. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferiprone profile page.

Pharmacology for FERRIPROX

Drug ClassIron Chelator
Mechanism of ActionIron Chelating Activity
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apopharma Inc
FERRIPROX
deferiprone
TABLET;ORAL021825-001Oct 14, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
TABLET;ORAL021825-001Oct 14, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
TABLET;ORAL021825-001Oct 14, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for FERRIPROX

Drugname Dosage Strength RLD Submissiondate
deferiproneTablets500 mgFerriprox1/29/2016

International Patent Family for Tradename: FERRIPROX

Country Document Number Estimated Expiration
Austria427107► Subscribe
CroatiaP20150083► Subscribe
South Korea101490721► Subscribe
Denmark1294379► Subscribe
South Africa201008374► Subscribe
Israel153733► Subscribe
Germany60138189► Subscribe
World Intellectual Property Organization (WIPO)2009129592► Subscribe
Brazil0112280► Subscribe
Eurasian Patent Organization022751► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Cantor Fitzgerald
Federal Trade Commission
AstraZeneca
Farmers Insurance
Teva
Colorcon
Healthtrust
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot